Draig Therapeutics

top of page

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

An Operating Partner at SV Health Investors, she describes how the company came together after reaching out to Cardiff University...

Company News

Jun 18

Cardiff-based Draig Therapeutics launched today in the neuro space with a total investment of $140 million, with lead program DT-101, an AMPA receptor PAM, ready for P2 in Major Depressive Disorder

Professor Simon Ward of Cardiff University’s Medicines Discovery Institute, and Scientific Co-founder and CSO Draig, describes the...

Company News

Jun 17

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

Cardiff-based Draig Therapeutics launched today in the neuro space with a total investment of $140 million, with lead program DT-101, an AMPA receptor PAM, ready for P2 in Major Depressive Disorder

Follow BiotechTV

Sponsors

Sponsor Spotlight